Furthermore, recent CVOTs have shown that SGLT2 inhibitors reduce the risk of HHF and cardiovascular death in patients with established heart failure (HF) and reduced ejection fraction, regardless of their diabetic status [2], and even in patients who were admitted due to worsening HF [3]. The gene discussed is SLC5A2; the disease is hydrops fetalis.